Quoin Pharmaceuticals, Ltd.
QNRXNasdaqHealthcare · Pharmaceutical Preparations · L3 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | −$15.8M | −$9.0M | −$8.7M | −$9.4M | −$21.5M |
| Total assets | $20.4M | $15.7M | $12.2M | $14.5M | $9.4M |
| Total liabilities | $7.3M | $6.5M | $6.5M | $7.1M | $8.7M |
| Equity | $13.1M | $9.2M | $5.7M | $7.4M | $657,032 |
| EPS (diluted) | — | — | — | — | — |
| Shares out. | 52.4M | 8.9M | 987,220 | 403,887 | 3.35B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −120.5%
- Return on assets
- −77.5%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 35.7%
- Debt / equity
- 0.55×
- Book value / share
- $0.25
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −11.1%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2/3Active Not Recruitingreadout ~2025-12-30Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
- Phase 2/3Recruitingreadout ~2025-12-30Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
- Phase 2/3Recruitingreadout ~2026-07-30Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
- Phase 2/3Recruitingreadout ~2027-01-31Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Adar1 Capital Management, LlcPassive (13G)May 15, 2026
- Stonepine Capital Management, LlcPassive (13G)May 15, 2026
- Woodline Partners LpPassive (13G)May 15, 2026
- Aberdeen Group PlcPassive (13G)Apr 29, 2026
- Integrated Core Strategies (Us) LlcPassive (13G)Feb 11, 2026
- Ikarian Capital, LlcPassive (13G)Feb 6, 2026
- Resolute Capital Asset Partners LlcPassive (13G)Dec 11, 2025
- Armistice Capital, LlcPassive (13G)May 15, 2025
- Myers MichaelActivist (13D)Jan 28, 2025
- Carter Denise P.Activist (13D)Jan 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 79,876 | 5.6 | -6.6% |
| Apr 30, 2026 | 85,556 | 2.9 | +6.3% |
| Apr 15, 2026 | 80,474 | 2.3 | -14.8% |
| Mar 31, 2026 | 94,409 | 1.0 | +1136.7% |
| Mar 13, 2026 | 7,634 | 1.0 | -48.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Results of operationsMar 26, 2026
- Regulation FD disclosure · Other material eventMar 11, 2026
- Regulation FD disclosure · Other material eventJan 20, 2026
- Director / officer changeNov 17, 2025
- Regulation FD disclosure · Other material eventNov 12, 2025
- Results of operationsNov 6, 2025
- Regulation FD disclosure · Other material eventOct 21, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 8-KFORM 8-KMay 7, 2026
- 10-QMay 7, 2026
- SCHEDULE 13G/AApr 29, 2026
- 4Mar 31, 2026
- 10-KMar 26, 2026
- 8-KFORM 8-KMar 26, 2026
- 8-KFORM 8-KMar 11, 2026
- SCHEDULE 13GFeb 17, 2026
- SCHEDULE 13GFeb 17, 2026
- SCHEDULE 13G/AFeb 11, 2026
- SCHEDULE 13G/AFeb 6, 2026
- 4OWNERSHIP DOCUMENTFeb 6, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.